Phoenix Nuclear Labs

Press Release

PNL Awarded $3.6 Million in Army Contracts

August 2nd, 2016 | Filed under: Press Release

Phoenix Nuclear Labs (PNL) announced today that it has been awarded multiple contracts by the U.S. Army totaling $3.6 million. Under these contracts, PNL will build an advanced neutron radiography system to detect defective munitions and demonstrate the ability to use their neutron generators to detect and identify concealed explosive threats.

HTA and SHINE Announce Moly-99 Supply Agreement

June 21st, 2016 | Filed under: Press Release

Beijing, China – HTA Co., Ltd. (HTA), the largest Chinese producer and distributor of radio-pharmaceuticals, and SHINE Medical Technologies (SHINE), a U.S. company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that the companies have entered into a strategic agreement for the supply of molybdenum-99 (moly-99). The supply agreement, which marks HTA’s first with a U.S. supplier of moly-99, demonstrates both companies’ ongoing commitment to ensuring that the medical imaging community has reliable and secure access to moly-99 to meet the needs of patients.

Phoenix Nuclear and SHINE Complete Unprecedented Neutron Production Run

March 22nd, 2016 | Filed under: Press Release

MONONA, Wis. – Phoenix Nuclear Labs (PNL) and SHINE Medical Technologies (SHINE) announced today that they successfully operated their accelerator-based neutron generator for 132 consecutive hours with greater than 97% uptime. This accomplishment represents an industry first for extended-operation reliability of a gas target neutron generator and is an important demonstration of the robustness of the PNL neutron generator, a key enabling technology for the SHINE medical isotope production facility.

NRC to Issue Construction Permit for SHINE Medical Isotope Facility

February 25th, 2016 | Filed under: Press Release

The Nuclear Regulatory Commission has authorized its staff to issue a construction permit for a first-of-a-kind facility dedicated to medical isotope production. The Commission, having completed a mandatory hearing, found the staff’s review of the SHINE Medical Technologies, Inc. application sufficient to make the necessary safety and environmental findings. This will be the first construction permit issued for either a non-power utilization or production facility by the NRC since 1985.

SHINE’s Founder and CEO Awarded Top Honors by UW-Madison College of Engineering

January 11th, 2016 | Filed under: Press Release

Madison, WI – The University of Wisconsin-Madison College of Engineering has awarded Dr. Greg Piefer, founder and CEO of SHINE Medical Technologies, Inc. (SHINE) the Early-Career Achievement Award. The award honors young alumni whose achievements stand out as exceptional, typically within 10 years of graduation.

It Takes Two: GE Healthcare and SHINE team up

November 9th, 2015 | Filed under: Press Release

CHALFONT ST. GILES, UK – 9 November 2015 –Today, SHINE and GE Healthcare announced they have successfully obtained pharmaceutical-grade Tc-99m from GE Healthcare’s Drytec™ (Technetium Tc99m Generator) For the Production of Sodium Pertechnetate for Tc99m Injection, using Mo-99 produced by SHINE’s innovative process.

SHINE Achieves Major Milestone on Path to Construction Permit Approval

October 26th, 2015 | Filed under: Press Release

Monona, WI – SHINE Medical Technologies, Inc., a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical tracers and cancer treatment elements, announced today that the staff of its primary regulator, the Nuclear Regulatory Commission (NRC), has completed their safety and environmental reviews and recommends approval of a Construction Permit for the SHINE facility.

SHINE is the first U.S. medical isotope producer to have reached this stage of the NRC permitting process since the 1960s.

Additional $2 Million Award for SHINE

October 21st, 2015 | Filed under: Press Release

Monona, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based medical isotope company, announced today that it has been awarded $1 million from the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) as part of a $2 million cooperative agreement. The new funding will continue acceleration of SHINE’s efforts to establish a reliable, domestic supply of molybdenum-99 (moly-99) without weapons-usable highly enriched uranium.

SHINE Signs License Agreement for SRNL Innovation

October 15th, 2015 | Filed under: Press Release

Monona, WI and Aiken, SC – Savannah River Nuclear Solutions, LLC (SRNS), the management and operating contractor for the U.S. Department of Energy’s Savannah River National Laboratory (SRNL), has granted SHINE Medical Technologies, Inc. (SHINE) an exclusive license on SRNL’s patented hydrogen isotope separation process for use in medical isotope production. SHINE is a Wisconsin-based company founded to produce medical isotopes using its safe, cost-effective and environmentally-friendly technology. The agreement with SRNS gives SHINE the right to use SRNL’s thermal cycling absorption process (TCAP) in its manufacturing facility. The use of TCAP provides the high-purity inputs needed for SHINE’s patented…read more +

National Science Foundation Award Helps SHINE Accelerate Efforts to Become a Major Domestic Producer of Iodine-131

June 30th, 2015 | Filed under: Press Release

Monona, WI – SHINE Medical Technologies, a Wisconsin-based medical isotope company, announced today that it has been awarded $150,000 from the National Science Foundation for Phase I of an SBIR (Small Business Innovation Research) Grant.